Aripiprazole versus placebo for schizophrenia

Area of Science:

• Psychiatry and Pharmacology
• Clinical Neuroscience
• Mental Health Treatment

Background:

• Schizophrenia treatment has evolved from typical to atypical antipsychotics.
• While effective for many, some patients show inadequate response or experience adverse effects.
• Existing antipsychotics can lead to poor compliance and increased relapse rates.

Purpose of the Study:

• To evaluate the efficacy and safety of aripiprazole versus placebo in schizophrenia treatment.
• To assess aripiprazole's impact on relapse rates and adverse effects.
• To determine aripiprazole's potential role in managing schizophrenia-like psychoses.

Main Methods:

• Systematic review of randomized controlled trials (RCTs) comparing aripiprazole with placebo.
• Searched major databases including MEDLINE, EMBASE, PsycINFO, and CENTRAL.
• Extracted and analyzed dichotomous and continuous data using fixed-effect models.

Main Results:

• Aripiprazole significantly reduced relapse rates in both short and medium terms compared to placebo.
• Fewer participants left aripiprazole treatment groups than placebo groups, indicating better compliance.
• Aripiprazole may decrease prolactin levels; insomnia and headaches were common but not significantly different between groups.

Conclusions:

• Aripiprazole demonstrates potential effectiveness in treating schizophrenia.
• It appears to have a lower risk of elevated prolactin and QTc interval prolongation.
• Further pragmatic, long-term RCTs are needed to establish its clinical practice role.